A study published in CHEST found that patients with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor therapy experienced improved cognitive processing, depression, and health-related quality of life over 6 months. Despite experiencing neuropsychological side effects such as insomnia, headache, brain fog, memory and concentration problems, patients still benefited from the treatment. The study involved 92 Italian adults and adolescents with cystic fibrosis. FEV1 percent predicted, BMI, depression scores, cognitive processing, and health-related quality of life all showed improvement over the course of the study. GI symptoms and adherence challenges also improved as months passed. Female patients reported higher incidences of insomnia, headache, brain fog, and concentration problems.
Source link
Neuropsychological side effects remain 6 months into cystic fibrosis triple therapy
